


BMS cell therapy operations and manufacturing

The complexity of delivering autologous CAR T cell therapies is unlike any other traditional biologic or small molecule medicine, using a patient’s own cells to start a highly sophisticated and personalized manufacturing process. Bristol Myers Squibb is advancing the field of cell therapy through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of-the-art facilities with cutting-edge technologies and highly trained manufacturing teams.

Cell therapy manufacturing footprint and network



By the numbers

*Data as of May 2024



8,700+

patients treated in clinical trial and commercial settings



4

BMS clinical and commercial manufacturing sites, with two additional facilities underway



4,600

talented and passionate people, working together with agility and urgency to deliver on the promise of cell therapy to patients

- Over 1,300 new hires in the past 12 months*



Over **20 years** and



\$17 billion

invested in this practice-changing therapy



2 approved

therapies



3+ investigational

cell therapies in clinical trials

Our long-term commitment

As we continue to expand our manufacturing network, BMS is committed to:



Delivering for our patients

Putting people, safety, quality and compliance first



Operational excellence

Advancing OpEx organizational capabilities to deliver organization efficiencies



Driving digital

Advanced digital plan technologies being implemented to ensure reliable supply

Each day, BMS employees around the world work together for patients, who are at the center of everything we do. We continue making significant investments to expand and optimize our global manufacturing network to bring cell therapy treatments to more patients in need.